Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026
Simultaneously, some cells undergo cell cycle arrest and become senescent owing to the inhibition of cyclin-dependent kinases mediated by p21 activation through the DDR pathway 11
Previous work shows that DSIP can inhibit hypoxia-induced reduction of mitochondrial respiratory activity and suggests that DSIPs antioxidant mechanisms could contribute to its neuroprotective effects
Over weeks and months, this pattern of stress response reactivation changes the equilibrium of essential hormones that regulate ovulation, sperm production, and sexual function
Most patients with BMI 40 will likely choose retatrutide for its superior results, while those with BMI 30-40 may prefer CagriSema's faster availability
Below, we discuss the most common therapeutic applications of epitalon and the science to support them